Content sponsored by Encoll Corporation.

Helicoll® is a highly bioactive and cell-conducive bioengineered skin substitute made of Type-I collagen (>97% pure), which serves as an acellular construct to enhance tissue regeneration for wound management. With a fully purified and uncross-linked molecule, Helicoll® provides an impressive 3,000 receptor sites per molecule for growth factors, particularly fibroblasts, making it an exceptional matrix for wound healing. Its resorbable properties promote the regeneration of blood vessels and support biologic cell migration.

In this article, we will explore the various indications of Helicoll® and how it facilitates rapid tissue regeneration, leading to accelerated wound healing.

Indications for Helicoll®

Venous ulcers:

Helicoll® offers a reliable treatment option for chronic ulcers by aiding in the regeneration of damaged tissues and expediting the healing process.

Diabetic ulcers:

Helicoll® has demonstrated efficacy in rapidly regenerating tissues and reducing the size of diabetic ulcers.                             

Pressure ulcers:

Helicoll® shows promise in treating pressure ulcers, promoting tissue regeneration, and facilitating faster wound closure, providing relief to patients

Skin donor sites for grafts:

Helicoll® effectively heals donor site wounds, enabling complete graft uptake while minimizing complications at the donor site.                        

2nd-degree burns:

Helicoll® aids in the healing of second-degree burns, promoting faster growth of granulation tissue and accelerating the overall healing process.

Trauma wounds:

Helicoll® is beneficial in treating various trauma wounds, including abrasions, lacerations, and skin tears, promoting faster healing and reducing complications.

Partial and full-thickness wounds:

Helicoll® has proven effectiveness in healing partial and full-thickness wounds, encouraging tissue regeneration and providing an optimal environment for healing.

Key Characteristics of Helicoll®

• High purity Type-I Collagen: Helicoll® is a patented reconstituted bioactive collagen sheet that is free of immunogenic proteins, lipids, and elastin.
• Faster Healing: Collagen phosphorylation in Helicoll® attracts cells, regenerates tissue, and stimulates blood capillaries and granulation within 4 to 5 days, providing a significant advantage in clinical data compared to other products.
• Innovative Technology: Helicoll®'s unique innovative features lie in the purity, nativity, structural integrity, and induced bioactivity of Type-I collagen.
• Pain Control:Clinical evidence supports that Helicoll® reduces pain compared to other standard wound care options.

Conclusion

Helicoll® Bioengineered Skin Substitute has been clinically proven to expedite wound healing due to its proprietary pure Type-I collagen, which reduces immunogenicity and promotes cell migration through enhanced neovascularity from Type-I collagen phosphorylation. Notably, it has unique clinical evidence for the formation of granulation and neovascularization within 4 to 5 days of application, resulting in relatively faster wound healing and tissue regeneration.

About the Company: EnColl Corporation is a California corporation that develops, manufactures and markets type I collagen-based products.

Industry Voices is brought to you by health care industry sponsors. All content is developed by the sponsoring company. HMP Global is not involved in the creation of this content.